The US Senate passes two pieces of Food and Drug Administration-related legislation, the New York Times reports.
A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.
On a conference call, the firm's CEO said that it and other industry players are pushing to postpone implementation of PAMA to no earlier than July 1, 2018.
Lawmakers approve a flat budget for the US National Science Foundation, but suggest how to spend it, ScienceInsider reports.
A House bill would increase the US National Institutes of Health budget by 3 percent, but prohibit it from funding research that uses fetal tissue.
The increase includes greater spending on Alzheimer's disease research, precision medicine, and cancer research initiatives.
Patients who've learned their genetic risk of disease worry about healthcare law changes in the US, Kaiser Health News reports.
Even with proposed cuts unlikely to materialize, the Atlantic's Ed Yong writes that the specter of them is still felt.
Paul Ryan, the Speaker of the House of Representatives, has appointed Patrick Soon-Shiong to a committee that will advise the president on health IT, Politico reports.
Entering a new chapter with a new leader, ACLA lends support to a draft bill that would regulate lab tests not as medical devices but as in vitro clinical tests.
The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.
A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.
Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.